Confirm Laboratory Hypoglycemia Before Extensive Work-Up
In a patient on tirzepatide reporting low capillary glucose values without laboratory confirmation, the first and most critical step is to obtain laboratory-measured plasma glucose during a symptomatic episode, as point-of-care glucose monitors are insufficient for diagnosing true hypoglycemia 1.
Initial Assessment
Since tirzepatide is not known to cause hypoglycemia when used as monotherapy 2, and the patient has only self-reported accucheck values, you must distinguish between:
- True hypoglycemia (requires laboratory confirmation)
- Inaccurate meter readings (common with point-of-care devices at low glucose levels)
- Pseudohypoglycemia (symptoms without actual low glucose)
Immediate Actions
Document Whipple's Triad during the next symptomatic episode:
- Symptoms consistent with hypoglycemia
- Laboratory-measured plasma glucose <55 mg/dL (3.0 mmol/L) 1
- Resolution of symptoms with glucose administration
Do not rely on accuchecks alone - the Endocrine Society explicitly states that "the decision to end the fast should be based on laboratory-measured plasma glucose concentrations, not those estimated with a point-of-care glucose monitor" 1
If Laboratory Hypoglycemia is Confirmed
Medication Review (Most Common Cause)
Immediately review all medications - drugs are the most common cause of hypoglycemia in non-diabetic patients 1:
- Screen for concomitant insulin, sulfonylureas, or meglitinides (these dramatically increase hypoglycemia risk when combined with tirzepatide) 3, 4
- Check for alcohol use
- Review all other medications that could contribute
Diagnostic Work-Up Protocol
If true hypoglycemia is documented and no obvious drug cause exists, follow the Endocrine Society's systematic approach 1:
During a spontaneous hypoglycemic episode (plasma glucose <55 mg/dL), obtain:
- Plasma glucose (laboratory)
- Insulin level
- C-peptide
- Proinsulin
- β-hydroxybutyrate
- Screen for oral hypoglycemic agents
- Insulin antibodies
Critical diagnostic thresholds for endogenous hyperinsulinism:
- Insulin ≥3.0 µU/mL (18 pmol/L)
- C-peptide ≥0.6 ng/mL (0.2 nmol/L)
- Proinsulin ≥5.0 pmol/L
- β-hydroxybutyrate ≤2.7 mmol/L
If Spontaneous Episode Cannot Be Captured
Perform a supervised 72-hour fast 1:
- Discontinue tirzepatide and all non-essential medications
- Monitor plasma glucose every 6 hours until <60 mg/dL, then every 1-2 hours
- End fast when glucose <45 mg/dL with symptoms OR <55 mg/dL if Whipple's triad previously documented
- At termination: obtain full panel above plus glucagon stimulation test (1.0 mg IV, measure glucose at 10,20,30 minutes)
Common Pitfall: Tirzepatide-Specific Considerations
While tirzepatide monotherapy does not typically cause hypoglycemia, recent case reports describe rare scenarios where it may contribute:
- Starvation ketoacidosis from severe appetite suppression and reduced caloric intake 5 - though this presents with ketoacidosis, not isolated hypoglycemia
- Euglycemic ketoacidosis when combined with SGLT2 inhibitors 6
- In Type 1 diabetes patients using tirzepatide off-label, symptomatic hypoglycemia occurred in 29% 4
Key distinction: These cases involved either inadequate caloric intake, concurrent diabetes medications, or Type 1 diabetes - not tirzepatide monotherapy in otherwise healthy individuals.
Management Algorithm
If no laboratory hypoglycemia is confirmed:
- Reassure patient
- Check meter accuracy
- Consider functional disorder if symptoms persist without documented low glucose 1
If laboratory hypoglycemia confirmed with tirzepatide alone:
- This is highly unusual - proceed with full endocrine evaluation as outlined above
- Consider critical illnesses, hormone deficiencies, non-islet cell tumors 1
- Evaluate for inadequate caloric intake or eating disorders
If hypoglycemia confirmed with concurrent diabetes medications: